CN101199618A - Shenling know luo capsule - Google Patents
Shenling know luo capsule Download PDFInfo
- Publication number
- CN101199618A CN101199618A CNA2007101448373A CN200710144837A CN101199618A CN 101199618 A CN101199618 A CN 101199618A CN A2007101448373 A CNA2007101448373 A CN A2007101448373A CN 200710144837 A CN200710144837 A CN 200710144837A CN 101199618 A CN101199618 A CN 101199618A
- Authority
- CN
- China
- Prior art keywords
- radix
- capsule
- shenling
- medicine
- luo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a Shenling collateral-dredging capsule which belongs to the Chinese patent medicine, the capsule is composed of Astragalus root, ginseng, ganoderma lucidum, caterpillar fungus, earthworm, hemlock parsley, angelica, lignum millettiae, safflower, achyranthes, semen persicae, radices paeoniae rubra, red sage root, cassia twigs and myrrh, the medicine is used for treating diabetes complicating peripheral neuropathy so as to reach effects of Yin nourishing and kidney strengthening and blood circulation promotion to remove meridian obstruction, as well as improving symptoms of acroanesthesia, ache and abnormal sensation diabetes caused by the complicating peripheral neuropathy, so the invention has advantages good curative effect and low toxic and side effect.
Description
Technical field
The invention belongs to Chinese patent medicine, relate generally to a kind of medicine that is used for the treatment of diabetes complicated peripheral neuropathy.
Background technology
Diabetes are a kind of endocrine metabolism diseases that belong to, be because body insulin secretion metabolic disease, a kind of chronic disease that is that hyperamization sugar increases because body insulin secretion relative deficiency causes metabolism disorder such as sugar, fat, protein and drains glycosuria.Diabetic peripheral neuropathy is one of common chronic complicating diseases, does not still have at present effectively and therapeutic method of reliable.The long-term blood glucose of diabetics is too high, Na
+-K
+-ATP enzyme activity reduces, and nervous tissue's energy is discharged be affected, thereby cause peripheral neuropathy, as peripheral neuritis, thereby causes great misery to the patient, and blood-vessel obstructive, spasm of muscles and vessels, numb limbs and tense tendons, pain are unbearably.
Summary of the invention
Purpose of the present invention just provides a kind of Shenling know luo capsule that is used for the treatment of diabetes complicated peripheral neuropathy, reaching the purpose of symptoms such as numb limbs and tense tendons that enriching yin and nourishing kidney, promoting blood circulation to remove obstruction in the collateral, the diabetes complicated peripheral neuropathy of improvement cause, pain, paraesthesia, is a kind of oral good medicine of being made up of natural drug.
The object of the present invention is achieved like this: the oral medicine Shenling know luo capsule for the treatment of diabetes complicated peripheral neuropathy is made up of the Radix Astragali, Radix Ginseng, Ganoderma, Cordyceps, Pheretima, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Caulis Spatholobi, Flos Carthami, Radix Achyranthis Bidentatae, Semen Persicae, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Ramulus Cinnamomi, Myrrha, and the components by weight of various medicines is: the Radix Astragali 80, Radix Ginseng 40, Ganoderma 40, Cordyceps 24, Pheretima 80, Rhizoma Chuanxiong 40, Radix Angelicae Sinensis 40, Caulis Spatholobi 80, Flos Carthami 40, Radix Achyranthis Bidentatae 40, Semen Persicae 40, Radix Paeoniae Rubra 40, Radix Salviae Miltiorrhizae 80, Ramulus Cinnamomi 40, Myrrha 40.
According to tcm theory, in the said medicine component, Radix Ginseng, the Radix Astragali are used to promote immunomodulating, promote metabolism to increase muscle power, thereby improve Na
+-K
+The vigor of-ATP enzyme; Ganoderma has significant analgesia role for nervous system, but not block nerves transmission; Cordyceps is the good medicine of treatment cardiovascular and cerebrovascular disease; Pheretima is apt to away scurry, and is the meridian dredging medicine good in the Chinese medicine; Rhizoma Chuanxiong is the good medicine of traditional Chinese medical science blood circulation promoting and blood stasis dispelling; Radix Angelicae Sinensis has promotion metabolism, effects such as blood sugar lowering; Caulis Spatholobi is the good medicine of promoting blood circulation to remove obstruction in the collateral; But the Flos Carthami blood fat reducing, coronary artery dilator, i.e. femoral artery; Radix Achyranthis Bidentatae has expansion peripheral blood vessel and analgesic effect; Radix Paeoniae Rubra has the effect of spasmolytic, pain relieving, blood vessel dilating; Radix Salviae Miltiorrhizae has and resists myocardial ischemia and the effect of expansion artery blood flow, still has to reduce lipid and to the sedation of nervus centralis; But the Semen Persicae blood circulation promoting and blood stasis dispelling, the anticoagulant effect; The Ramulus Cinnamomi removing obstruction in the collateral to relieve pain; But Myrrha promoting blood circulation and stopping pain.In sum, the effect of this prescription is reliable.
The present invention has carried out toxicity test and clinical practice:
Toxicity test: it is unit of weight with the gram that above-mentioned laboratory sample is got its each drug component: Radix Astragali 80g, Radix Ginseng 40g, Ganoderma 40g, Cordyceps 24g, Pheretima 80g, Rhizoma Chuanxiong 40g, Radix Angelicae Sinensis 40g, Caulis Spatholobi 80g, Flos Carthami 40g, Radix Achyranthis Bidentatae 40g, Semen Persicae 40g, Radix Paeoniae Rubra 40g, Radix Salviae Miltiorrhizae 80g, Ramulus Cinnamomi 40g, Myrrha 40g, through being ground into fine powder, decocting is made suspension after boiling and pulverizing with concentrate drying, by kg body weight give medicine g number calculate dosage to mouse stomach administration do acute toxicity test, any toxic reaction does not appear in the result, observed 7 days after the administration, none animal dead fails to measure LD
50Experiment conclusion: as calculated, zooperal dosis tolerata is 390.6 times of the maximum dose of clinical per day for adults.
Above-mentioned sample is pressed the dosage of 12g/Kg and 3g/Kg respectively and given rat long term administration in 60 days, carry out long term toxicity test, the result shows that ANOMALOUS VARIATIONS does not all appear in indexs such as two groups of general situations of rat, growth promoter, routine blood test, hepatic and renal function, with normal control group comparing difference not significantly (P＜0.05), pathological change is not also seen by histopathologic examination; The proof Shenling know luo capsule belongs to no obvious toxic-side effects, and the dosage safety of clinical usefulness is reliable.Test report unit and material are preserved the place: Chinese medicine research department of Heilongjiang University of Chinese Medicine.
Pharmacodynamic test of active extract: above-mentioned experimental drug is pressed 2g/Kg and the administration of two dosage groups of 0.5g/Kg, laboratory animal is divided into four experimental grouies at random investigates to metabolism of diabetic sciatic nerve polyhydric alcohol and Na
+-K
+The influence of-ATP enzyme activity, the result shows that content of sciatic sorbitol in alloxan diabetes rats and normal control group obviously raise, simultaneously inositol content and Na
+-K
+-ATP enzyme activity obviously reduces (P＜0.01) than normal group.And the sorbitol accumulation obviously reduces Na in Shenling know luo capsule treatment back nerve
+-K
+-ATP enzyme activity obviously rises.Wherein Shenling know luo capsule high dose group and model group compare P＜0.01, and low dose group also＜0.05; In addition, the Shenling know luo capsule high dose group still has certain influence to the blood glucose metabolism, and slight hypoglycemic activity is promptly arranged; But to the not remarkable P of the influence of inositol content＜0.05; This proof can obviously reduce the intracellular sorbitol content of diabetic sciatic nerve after with medicine of the present invention, improve Na
+-K
+-ATP enzyme activity.
The observation of curative effect of clinical trial:
Standard by clinical observation plan formulation, publish " diabetology " and tcm diagnosis new edition teaching material related content with reference to people's health, and assert in conjunction with clinical practice, observation case 178 examples that will be diagnosed as diabetes in the attached First Academy of Heilongjiang University of Chinese Medicine are divided into administration group and matched group, administration group 132 examples give 4/time of Shenling know luo capsules, 3 times/day; Matched group 46 examples give 4/time of Rhizoma Gastrodiae Pilulaes, 3 times/day.
Curative effect judging standard is:
Clinical recovering: clinical symptoms disappears substantially, and it is normal that tendon reflex recovers, and the inspection of science of laboratorys such as nerve conduction velocity is normal substantially.
Produce effects: clinical symptoms is obviously improved; Tendon reflex and nerve conduction velocity all have clear improvement.
Effectively: clinical symptom relief, tendon reflex and nerve conduction velocity are slightly improved.
Invalid: treating after a course of treatment symptom and sign does not have and improves or the state of an illness continues development person.
The equal medication of experimental group and matched group one month was the course of treatment, and two groups of total effectses see Table:
Table: peripheral neuropathy treatment clinical observation result
| Group | The example number | Cure in the recent period (%) | Produce effects number (%) | Significant figure (%) | Invalid number (%) | Total effective rate (%) |
| The administration group | 132 | 10 (7.5) | 24 (18.2) | 82 (62.1) | 16 (12.1) | 87.8 |
| Matched group | 46 | 1 (2.2) | 10 (21.7) | 22 (47.8) | 13 (28.3) | 71.7 |
Above result shows medication therapy groups total effective rate 87.8% of the present invention, significantly better than the Rhizoma Gastrodiae Pilulae group.P＜0.05 is analysed in credit by statistics, and there were significant differences for the two.
Show that through 132 routine clinical observation result medicine of the present invention all has clear improvement to the symptom and the sign of diabetic peripheral neuropathy, nerve conduction velocity and tendon reflex are had tangible recovery, total effective rate reaches 87.8%.Prove that medicine of the present invention is being a medicine preferably aspect the treatment diabetic peripheral neuropathy.
Medicine of the present invention is a traditional Chinese medical science prescription, adopts crude drug, prescription science uniqueness, and toxic and side effects is low, and good effect has been cured patient's several ten thousand examples because of the peripheral neuropathy that must diabetes causes, is subjected to the favorable comment of extensive patients.
The specific embodiment
Describe the present invention for embodiment below.
The present invention is mixed with Shenling know luo capsule with natural drug, is made up of the Radix Astragali, Radix Ginseng, Ganoderma, Cordyceps, Pheretima, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Caulis Spatholobi, Flos Carthami, Radix Achyranthis Bidentatae, Semen Persicae, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Ramulus Cinnamomi, Myrrha.Proportioning component by various medicines is taken out: Unit Weight is gram: the Radix Astragali 80, Radix Ginseng 40, Ganoderma 40, Cordyceps 24, Pheretima 80, Rhizoma Chuanxiong 40, Radix Angelicae Sinensis 40, Caulis Spatholobi 80, Flos Carthami 40, Radix Achyranthis Bidentatae 40, Semen Persicae 40, Radix Paeoniae Rubra 40, Radix Salviae Miltiorrhizae 80, Ramulus Cinnamomi 40, Myrrha 40; During making, the Radix Astragali, Ganoderma, Caulis Spatholobi, Flos Carthami, Radix Achyranthis Bidentatae, Semen Persicae, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Myrrha are given as one thinks fit cataclasm, decoct with water twice, add 10 times of amounts decocted 2.5 hours at every turn, gradation filters, merging filtrate, and filtrate is condensed into the extractum of relative density 1.35 under 80 ℃ of temperature; Radix Ginseng, Cordyceps, Pheretima, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Ramulus Cinnamomi are ground into fine powder, mix with above-mentioned extractum, and is dry below 70 ℃, is ground into fine powder, incapsulates to get final product.Every heavy 0.4g makes Shenling know luo capsule.
This medicine thinks that through the written instructions of black powder inspection file this medicine preparation technology is reasonable, and quality standard is than standard, and stability testing method is feasible, and pharmacodynamics and toxicology interrelated data meet the relevant technologies requirement of provisions for new drugs approval basically, and Department of Public Health of Shanxi Province's evaluation is agreed to produce.
Claims (1)
1. Shenling know luo capsule, comprise the Radix Astragali, Radix Ginseng, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Ramulus Cinnamomi, it is characterized in that the components by weight of the various medicines of this capsule is: the Radix Astragali 80, Radix Ginseng 40, Ganoderma 40, Cordyceps 24, Pheretima 80, Rhizoma Chuanxiong 40, Radix Angelicae Sinensis 40, Caulis Spatholobi 80, Flos Carthami 40, Radix Achyranthis Bidentatae 40, Semen Persicae 40, Radix Paeoniae Rubra 40, Radix Salviae Miltiorrhizae 80, Ramulus Cinnamomi 40, Myrrha 40.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101448373A CN101199618A (en) | 2007-12-17 | 2007-12-17 | Shenling know luo capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101448373A CN101199618A (en) | 2007-12-17 | 2007-12-17 | Shenling know luo capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101199618A true CN101199618A (en) | 2008-06-18 |
Family
ID=39515100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101448373A Pending CN101199618A (en) | 2007-12-17 | 2007-12-17 | Shenling know luo capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101199618A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178758A (en) * | 2011-04-29 | 2011-09-14 | 薛红云 | Medicament for treating peripheral nerve of diabetes |
| CN102309575A (en) * | 2010-06-29 | 2012-01-11 | 山东步长制药有限公司 | Application of medicinal composition in preparing medicament for treating diabetic complication |
| CN102793768A (en) * | 2011-05-27 | 2012-11-28 | 李军 | Ginseng-ganodorma lucidum meridian-dredging capsule and production process thereof |
| CN102170894B (en) * | 2009-06-22 | 2013-04-10 | 怀特生技新药股份有限公司 | A pharmaceutical composition with the effect of treating diabetes |
| CN103610769A (en) * | 2013-09-24 | 2014-03-05 | 陆群英 | Diabetic peripheral neuropathy treatment traditional Chinese medicine composition |
| CN104127567A (en) * | 2014-08-19 | 2014-11-05 | 厉惠 | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy |
| CN104147491A (en) * | 2014-06-19 | 2014-11-19 | 张新成 | Oral traditional Chinese medicine formula for treating local leg numbness and preparation method thereof |
| CN104857254A (en) * | 2015-05-17 | 2015-08-26 | 申洪恩 | Drug for treating hand and foot numbness diseases and production method thereof |
| CN105616706A (en) * | 2016-03-22 | 2016-06-01 | 陈金锁 | Shenling (panax quinquefolius and ganoderma lucidum) granules for strengthening body resistance and preparation method thereof |
| CN107456466A (en) * | 2009-04-29 | 2017-12-12 | 培力(香港)健康产品有限公司 | Neuroprotective glossy ganoderma composition and its application method |
-
2007
- 2007-12-17 CN CNA2007101448373A patent/CN101199618A/en active Pending
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107456466A (en) * | 2009-04-29 | 2017-12-12 | 培力(香港)健康产品有限公司 | Neuroprotective glossy ganoderma composition and its application method |
| CN102170894B (en) * | 2009-06-22 | 2013-04-10 | 怀特生技新药股份有限公司 | A pharmaceutical composition with the effect of treating diabetes |
| CN102309575A (en) * | 2010-06-29 | 2012-01-11 | 山东步长制药有限公司 | Application of medicinal composition in preparing medicament for treating diabetic complication |
| CN102178758A (en) * | 2011-04-29 | 2011-09-14 | 薛红云 | Medicament for treating peripheral nerve of diabetes |
| CN102793768A (en) * | 2011-05-27 | 2012-11-28 | 李军 | Ginseng-ganodorma lucidum meridian-dredging capsule and production process thereof |
| CN103610769B (en) * | 2013-09-24 | 2015-07-22 | 陆群英 | Diabetic peripheral neuropathy treatment traditional Chinese medicine composition |
| CN103610769A (en) * | 2013-09-24 | 2014-03-05 | 陆群英 | Diabetic peripheral neuropathy treatment traditional Chinese medicine composition |
| CN104147491A (en) * | 2014-06-19 | 2014-11-19 | 张新成 | Oral traditional Chinese medicine formula for treating local leg numbness and preparation method thereof |
| CN104127567B (en) * | 2014-08-19 | 2016-04-06 | 厉惠 | A kind of Chinese medicine composition for the treatment of diabetic peripheral neuropathy |
| CN104127567A (en) * | 2014-08-19 | 2014-11-05 | 厉惠 | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy |
| CN104857254A (en) * | 2015-05-17 | 2015-08-26 | 申洪恩 | Drug for treating hand and foot numbness diseases and production method thereof |
| CN105616706A (en) * | 2016-03-22 | 2016-06-01 | 陈金锁 | Shenling (panax quinquefolius and ganoderma lucidum) granules for strengthening body resistance and preparation method thereof |
| CN105616706B (en) * | 2016-03-22 | 2020-07-07 | 陈金锁 | Shenling granule for strengthening body resistance and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102772745B (en) | Chinese medicinal preparation for treating cancer and preparation method thereof | |
| CN101199618A (en) | Shenling know luo capsule | |
| CN102973685B (en) | Anti-fatigue traditional Chinese medicine preparation and preparation method thereof | |
| CN102671137B (en) | Medicine composition for treating diabetic nephropathy and preparation method of medicine composition | |
| CN101708237B (en) | Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN101204464A (en) | Tianqi capsule for Kidney-Reinforcing | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN103948888A (en) | Traditional Chinese medicinal preparation for treating neurasthenia | |
| CN101810826B (en) | Chinese medicament for treating liver cancer | |
| CN101433586B (en) | Medicament for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN101279034B (en) | Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof | |
| CN100388945C (en) | Fatty liver treating notoginseng prepn and its prepn process | |
| CN106177759B (en) | A kind of compound Chinese medicinal preparation and its preparation process for treating coronary disease and angina pectoris | |
| CN101195003B (en) | Proprietary Chinese medicine for treating apoplexy and sequela | |
| CN112451618A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy | |
| CN105343675A (en) | Traditional Chinese medicine preparation for treating adiposis and preparation method thereof | |
| CN105055967A (en) | Compound health care product having auxiliary blood sugar reducing function and preparation method | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN115624582B (en) | New prescription for treating knee pain and preparation method and application thereof | |
| CN103784893A (en) | Medicine for treating sequela of cerebra apoplexy | |
| CN115645493B (en) | Traditional Chinese medicine preparation for treating chronic kidney disease stage 3 and preparation method thereof | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN100525822C (en) | Capsule for treating diabetic nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080618 |